Cargando…

Vaccination with nanoparticles combined with micro-adjuvants protects against cancer

BACKGROUND: Induction of strong T cell responses, in particular cytotoxic T cells, is a key for the generation of efficacious therapeutic cancer vaccines which yet, remains a major challenge for the vaccine developing world. Here we demonstrate that it is possible to harness the physiological proper...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohsen, Mona O., Heath, Matthew D., Cabral-Miranda, Gustavo, Lipp, Cyrill, Zeltins, Andris, Sande, Marcos, Stein, Jens V., Riether, Carsten, Roesti, Elisa, Zha, Lisha, Engroff, Paul, El-Turabi, Aadil, Kundig, Thomas M., Vogel, Monique, Skinner, Murray A., Speiser, Daniel E., Knuth, Alexander, Kramer, Matthias F., Bachmann, Martin F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485085/ https://www.ncbi.nlm.nih.gov/pubmed/31027511 http://dx.doi.org/10.1186/s40425-019-0587-z

Ejemplares similares

Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer
por: Mohsen, Mona O., et al.
Publicado: (2019)

Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine
por: Mohsen, Mona O., et al.
Publicado: (2019)

Type of RNA Packed in VLPs Impacts IgG Class Switching—Implications for an Influenza Vaccine Design
por: C. Gomes, Ariane, et al.
Publicado: (2019)

A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain
por: Chang, Xinyue, et al.
Publicado: (2021)

SARS-CoV-2 structural features may explain limited neutralizing-antibody responses
por: Bachmann, Martin F., et al.
Publicado: (2021)

Vaccination using mutated receptor binding domains of SARS-CoV-2: Evidence for partial immune escape but not serotype formation
por: Chang, Xinyue, et al.
Publicado: (2023)

The Prospects of an Active Vaccine Against Asthma Targeting IL-5
por: Bachmann, Martin F., et al.
Publicado: (2018)

Vaccination Against Amyloidogenic Aggregates in Pancreatic Islets Prevents Development of Type 2 Diabetes Mellitus
por: Roesti, Elisa S., et al.
Publicado: (2020)

Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis
por: von Loga, Isabell S, et al.
Publicado: (2019)

Induction of Broadly Cross-Reactive Antibodies by Displaying Receptor Binding Domains of SARS-CoV-2 on Virus-like Particles
por: Chang, Xinyue, et al.
Publicado: (2022)

Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax
por: Cabral-Miranda, Gustavo, et al.
Publicado: (2017)

Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2022)

Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy
por: Zeltins, Andris, et al.
Publicado: (2017)

Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2021)

Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection
por: Cabral-Miranda, Gustavo, et al.
Publicado: (2019)

Correction: Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72
por: Cabral-Miranda, Gustavo, et al.
Publicado: (2020)

Virus‐like particles for vaccination against cancer
por: Mohsen, Mona O., et al.
Publicado: (2019)

Active vaccination against interleukin‐5 as long‐term treatment for insect‐bite hypersensitivity in horses
por: Fettelschoss‐Gabriel, Antonia, et al.
Publicado: (2018)

DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines
por: Cabral-Miranda, Gustavo, et al.
Publicado: (2018)

Low‐affinity but high‐avidity interactions may offer an explanation for IgE‐mediated allergen cross‐reactivity
por: Chang, Xinyue, et al.
Publicado: (2021)

Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines
por: Gomes, Ariane C., et al.
Publicado: (2017)

Neutralization of MERS coronavirus through a scalable nanoparticle vaccine
por: Mohsen, Mona O., et al.
Publicado: (2021)

In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma
por: Mohsen, Mona O, et al.
Publicado: (2022)

BNT162b2 mRNA COVID‐19 vaccine induces antibodies of broader cross‐reactivity than natural infection, but recognition of mutant viruses is up to 10‐fold reduced
por: Chang, Xinyue, et al.
Publicado: (2021)

Construction and Characterization of Virus-Like Particles: A Review
por: Zeltins, Andris
Publicado: (2012)

Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT(®))
por: Heath, Matthew D., et al.
Publicado: (2020)

Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor‐binding domain mutations: Receptor affinity versus neutralization of receptor interaction
por: Vogel, Monique, et al.
Publicado: (2021)

Comparison of Bacterial Expression Systems Based on Potato Virus Y-like Particles for Vaccine Generation
por: Ogrina, Anete, et al.
Publicado: (2022)

Bacterial expression systems based on Tymovirus-like particles for the presentation of vaccine antigens
por: Ogrina, Anete, et al.
Publicado: (2023)

Recent Advances in the Use of Plant Virus-Like Particles as Vaccines
por: Balke, Ina, et al.
Publicado: (2020)

A scalable and highly immunogenic virus‐like particle‐based vaccine against SARS‐CoV‐2
por: Mohsen, Mona O., et al.
Publicado: (2021)

Intranasal administration of a VLP‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern
por: Rothen, Dominik A., et al.
Publicado: (2022)

TLR7 Signaling Shapes and Maintains Antibody Diversity Upon Virus-Like Particle Immunization
por: Chang, Xinyue, et al.
Publicado: (2022)

Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2022)

Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles
por: Doucet, Marika, et al.
Publicado: (2017)

Microcrystalline Tyrosine (MCT(®)): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria
por: Cabral-Miranda, Gustavo, et al.
Publicado: (2017)

Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism
por: Bachmann, Martin F., et al.
Publicado: (2022)

Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles
por: Zha, Lisha, et al.
Publicado: (2021)

Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System
por: Mohsen, Mona O., et al.
Publicado: (2018)

Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases
por: Klimek, Ludger, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nc2154vfhp9v7lf88fsslocdgn